Received Apr 9, 2026
Reports are unverified and do not show that a vaccine caused an event. Full disclaimer
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| MNQ | MENINGOCOCCAL CONJUGATE (MENVEO) | NOVARTIS VACCINES AND DIAGNOSTICS | UNK | UNK | SC |
Menveo was given Subcutaneous, when can it be given IM; This non-serious case was reported by a consumer via interactive digital media and described the occurrence of intramuscular formulation administered by other route in a patient who received Men ACWY-CRM NVS (Menveo) for prophylaxis. On an unknown date, the patient received Menveo (subcutaneous). On an unknown date, an unknown time after receiving Menveo, the patient experienced intramuscular formulation administered by other route (Verbatim: Menveo was given Subcutaneous, when can it be given IM). The outcome of the intramuscular formulation administered by other route was not applicable. Additional Information: GSK receipt date 09-MAR-2026 This case was reported by a consumer via interactive digital media. The reporter asked if Menveo could be given intramuscular on the same day as the patient received it subcutaneously. The batch number was not provided, and we are unable to contact the reporter.